Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Conditions
Interventions
Dupilumab
Placebo
Locations
84
United States
Birmingham, Alabama, United States
Mobile, Alabama, United States
Tucson, Arizona, United States
Bakersfield, California, United States
San Diego, California, United States
Santa Monica, California, United States
Start Date
May 1, 2013
Primary Completion Date
May 1, 2014
Completion Date
September 1, 2014
Last Updated
August 28, 2017
NCT07298395
NCT07217015
NCT06116526
NCT06461897
NCT07262983
NCT06389136
Lead Sponsor
Regeneron Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions